3.10: Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.

Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression of latent tuberculosis infection into active TB disease. Treatment options include the following.

• Isoniazid (INH) daily for nine months
• INH and Rifapentine (RPT) once weekly for three months under direct observation
• Rifampin (RIF) daily for four months

Active TB Disease: Treatment for active TB usually involves a two-phase approach.

• Initial Phase: This involves taking four medications—Isoniazid (INH), Rifampin (RIF), Ethambutol (EMB), and Pyrazinamide (PZA)—for two months. The precise regimen may be adjusted based on the patient's response to treatment and the strain of TB.

• Continuation Phase: This phase lasts at least four months and typically involves taking INH and RIF.

Further, drug-resistant tuberculosis includes multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis.

• Multidrug-resistant tuberculosis is a form of disease that does not respond to at least INH and RIF, the two most potent anti-TB drugs.

• Extensively drug-resistant tuberculosis represents an advanced stage of multidrug-resistant TB, with resistance not only to fluoroquinolone categories but also to at least one of three injectable second-line medications.

Treatment for these forms of TB must be individualized and typically involve a longer duration of therapy. When first-line drugs fail to eradicate the bacteria that cause TB, more second-line drugs are used to treat tuberculosis. These include fluoroquinolones such as levofloxacin and moxifloxacin and aminoglycosides such as streptomycin, ethambutol, and cycloserine.

It is essential that a healthcare professional supervise all tuberculosis patients, ensuring strict adherence to the prescribed treatment to prevent drug resistance and treatment ineffectiveness. In a hospital setting, TB patients must be placed on droplet precautions, with healthcare providers wearing a gown, gloves, an N95 mask, and protective eyewear. Additionally, patients should be housed in a negative pressure room or a room equipped with a HEPA filter.

Additionally, Directly Observed Therapy (DOT) is a strategy for monitoring tuberculosis treatment. This approach involves healthcare providers or trained health workers watching patients take their TB medications to ensure adherence. DOT can be administered in various settings, including clinics, hospitals, and the patient's home.

Proper nutrition and infection control measures are also essential for successful TB treatment. Following a well-rounded diet abundant in essential vitamins, minerals, and protein can fortify the immune system and facilitate recovery. It is also necessary to maintain good hygiene and follow proper cough etiquette, which is vital for TB patients to prevent disease transmission to others.

Finally, regular follow-up and monitoring are crucial components of TB treatment. Patients should undergo monthly sputum culture testing to ensure they respond well to treatment, and a healthcare provider should promptly address any side effects or complications. With proper medical management and support, TB can be successfully treated and cured. Individuals with latent or active TB need to seek medical care and follow their prescribed treatment regimen, not only to protect their health, but also to prevent the spread of this infectious disease.

Collaborative care for pulmonary tuberculosis involves a prolonged medication course tailored to drug-susceptible or drug-resistant tuberculosis.

Drug-susceptible tuberculosis refers to strains of tuberculosis that are sensitive to the standard first-line anti-tuberculosis drugs, like Isoniazid, Rifampin, Pyrazinamide, and Ethambutol.

These drugs are administered in combination orally once a day for eight weeks during the initial phase.

The continuation phase of treatment then includes Isoniazid and Rifampin for four or seven months.

In contrast, drug-resistant tuberculosis occurs when the patient becomes resistant to at least one of the first-line drugs, often due to incorrect dosage or premature treatment termination. It requires second-line drugs such as Fluoroquinolones.

Directly Observed Therapy or DOT is the preferred strategy to ensure all patients take their medications promptly, where a designated person observes the patient swalloing the medication to prevent nonadherence and multidrug resistance.

Finally, continuous patient monitoring, including monthly assessments of sputum culture, liver enzymes, creatinine, and blood urea nitrogen, is necessary to evaluate treatment effectiveness.

• Pulmonary Tuberculosis (PTB) - A contagious bacterial infection that primarily affects the lungs.
• Latent Tuberculosis Infection - A state where TB bacteria are present but are not causing illness or symptoms.
• Active TB Disease - A condition where TB bacteria cause severe symptoms and can spread to others.
• Drug-resistant Tuberculosis - A form of TB that does not respond to standard anti-TB medications.
• Directly Observed Therapy (DOT) - A strategy for ensuring patients strictly adhere to their TB treatment regimen.

• Define Pulmonary Tuberculosis (PTB) – Explain what it is (e.g., PTB).
• Contrast Latent vs Active TB – Explain key differences (e.g., symptoms and contagiousness).
• Explore Anti-Tuberculosis Drugs – Describe different types of TB drugs and their uses (e.g., Isoniazid and Rifampin).
• Explain Drug-resistant Tuberculosis – Description of what happens when TB does not respond to normal therapy.
• Apply Directly Observed Therapy (DOT) in Context – Explain how DOT ensures adherence to treatment.

• What is Pulmonary Tuberculosis and how does it affect the body?
• What differentiates Latent TB from Active TB?
• What are the main strategies for managing Pulmonary Tuberculosis?

• Students – Understand How the concept of Pulmonary Tuberculosis supports student understanding of infectious diseases
• Educators – Provides a clear framework it helps with teaching about infectious diseases
• Researchers – Relevance for studying TB and its treatment strategies
• Healthcare Professionals – Insight into the management and treatment of Pulmonary Tuberculosis